Most of the early therapeutics monoclonal antibody (mAb) products required parenteral intravenous administration. However, the ability to subcutaneously deliver small volumes (typically, ~1 mL) of highly concentrated (often, >150 mg/mL) antibody solutions is highly desirable from the perspective of patient convenience and compliance, particularly for chronic and/or home use. High concentration mAb products are therefore increasingly being developed in a variety of indications. A potential issue faced during the development of such products is high viscosity which can result in challenges during manufacturing, processing and administration. A number of different formulation and processing approaches have been suggested to lower the viscosity of antibody solutions at high concentrations. However, practical avenues for addressing viscosity, once a molecule has been selected for commercial development, are limited and resource-intensive. In this talk, I shall describe our attempts to understand molecular attributes that underpin concentration dependent viscosity behaviors of antibody solutions. The insights gained from these studies helped us develop a simple screen to 'red flag' therapeutic mAb candidates with potential viscosity issues at high concentrations and to rationally design variants of a viscosity challenged antibody with reduced viscosity.
